Oppenheimer Reiterates Perform on Editas Medicine, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has reiterated a 'Perform' rating on Editas Medicine (NASDAQ:EDIT) and maintained a $12 price target.
August 04, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst has reiterated a 'Perform' rating on Editas Medicine and maintained a $12 price target.
The news is directly about Editas Medicine and its stock rating by Oppenheimer. The 'Perform' rating and $12 price target have been maintained, indicating no change in the analyst's view of the company. This is likely to have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100